ATR and non-small cell lung carcinoma: However, stratified analysis revealed that ATR inhibitors achieved favorable objective response rates (ORR) and significantly reduced hazard ratios (HRs) for median progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer (NSCLC).